- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05607693
A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects
May 12, 2023 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Multi-Center, Open- Label, Single-Arm Phase 1 QT/QTc Study of SHR3680 in Subjects With Castration-Resistant Prostate Cancer
The purpose of this study is to determine whether daily treatment with SHR3680 affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
52
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: YIKE WANG, Pharm.D
- Phone Number: +86-134-0862-8814
- Email: yike.wang@hengrui.com
Study Contact Backup
- Name: Shaorong Li, Ph.D
- Phone Number: +86-180-0162-4511
- Email: shaorong.li@hengrui.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300000
- Recruiting
- Cancer Hospital of Tianjin
-
Contact:
- Xin Yao, Doctor
- Phone Number: 022-23340123-3100
- Email: yaoxin@tjmuch.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male between 18 years to 75 years of age;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- Expected survival of at least 6 months;
- Histologically or cytologically confirmed adenocarcinoma of the prostate without indication of neuroendocrine or small cell features; nonmetastatic castration-resistant prostate cancer (NM-CRPC) or metastatic castration-resistant prostate cancer (mCRPC) ;
- Be surgically or medically castrated and if treated with a gonadotropin releasing hormone analog (ie, patient who has not undergone bilateral orchiectomy), then this therapy must have been initiated at least 4 weeks prior to Day 1 and must be continued throughout the study;
- Castrated level of testosterone at screening (≦ 50 ng/dL or 1.73 nmol/L);
Organ function level must meet the following requirements (blood transfusion or hematopoietic growth factor therapy was not received within 2 weeks before blood test):
- ANC≧1.5×109/L;
- PLT≧80×109/L;
- Hb≧90 g/L;
- TBIL≦1.5×ULN;
- ALT and AST≦2.5×ULN;
- BUN and Cr≦1.5×ULN;
- GFR≧60ml/min/1.73m2;
- 12-lead ECG: heart rate ≥ 50 beats/min, PR interval within 110-220 ms (including both ends), QTc interval corrected according to Fridericia 's criteria (QTcF) < 470 msec. Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiography;
- Able to complete the study as required by the protocol;
- Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions.
Exclusion Criteria:
- Washout period of any previous anti-tumor therapy (including radiotherapy, chemotherapy, surgery, molecular targeted therapy, immunotherapy, androgen receptor antagonists, CYP-17 inhibitors, 5α-reductase inhibitors, estrogen, progesterone drugs, etc.) to the of the first dose of this study drug is < 4 weeks;
- Plan to receive any other anti-tumor therapy during the treatment phase in this trial;
- Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 4 weeks;
- Known brain metastases;
- history of epilepsy, or past medical history of disease that can induce seizures (including transient ischemic attack history, cerebral stroke (except cerebral ischemic lesions only found in imaging test), brain trauma with disturbance of consciousness requiring hospitalization) within 12 months before the first dose of the study drug;
- past medical history of the following diseases within 6 months before screening: myocardial infarction, severe/unstable angina, NYHA class II-IV cardiac insufficiency, ≥ Grade 2 sustained arrhythmia (graded based on NCI CTCAE 5.0), heart failure, grade II-III atrioventricular block, complete left bundle branch block, atrial fibrillation of any grade, coronary/peripheral artery bypass graft or stenting, cerebrovascular accident (including transient ischemic attack), pulmonary embolism, deep vein thrombosis;
- Inability to swallow, chronic diarrhea and intestinal obstruction, or the presence of multiple other factors affecting drug administration and absorption;
- Patients with active HBV or HCV infection (HBV copy number ≥ 104 copies/mL, HCV copy number ≥ 103 copies/mL);
- Patients with immunodeficiency disease history (including HIV test positive, other acquired or congenital immunodeficiency diseases) or organ transplantation history;
- Patients who are unwilling to take protocol-specified contraceptive measures throughout the study treatment period and within 3 months after the last dose;
- History of significant hypersensitivity, intolerance, or allergy to any drug compound or known allergy to SHR3680 or the excipients;
- Excessive smoking (≥ 5 cigarettes/day) within 6 months before screening or smoking within 48 h before the first dose, or positive at nicotine screening test, and can't abstain from smoking during the study; History of drug abuse, positive at drug abuse screening, or history of any drug use in the past 6 months;
- History of alcoholism or regular alcohol consumption within 6 months before screening, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer with 5% alcohol or 45 mL of spirits with 40% alcohol or 150 mL of wine with 12% alcohol) or drinking within 48 h before the first dose, or positive at alcohol breath test on the day of admission, or unable to abstain during the study;
- Subjects who took any vitamins, health products or herbal medicine within 14 days before dosing;
- Subjects who took any beverage or food containing grapefruit, xanthine, caffeine, or alcohol within 48 hours before dosing; strenuous exercise; or other factors which affect drug absorption, distribution, metabolism, excretion, etc;
- Abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN + 4 seconds or APTT > 1.5 ULN), bleeding tendency or on thrombolytic therapy;
- Patients with implantable pacemaker and automatic implantable cardioverter defibrillator;
- Personal or family history of long QT syndrome;
- Use of Medications that prolong QT/QTc interval or with risk of torsades de pointes (TdP) within 7 days prior administration of study drug;
- Significant history or clinical manifestation of concomitant diseases or other situations that put serious hazards to the patient' s safety, or affect the patient 's completion of the study, as determined by the Investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR3680
|
Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Delta QTc Fridericia (QTcF)
Time Frame: Day -1 and Day 1 and Day 17
|
Mean change from baseline in QTcF as measured based on triplicate electrocardiograms extracted from continuous 12-lead Holter monitor recordings after study drug intake.
|
Day -1 and Day 1 and Day 17
|
Concentration-delta QTcF relationship
Time Frame: Day -1 and Day 1 and Day 17
|
Relationship between SHR3680 plasma concentration and delta QTcF based on linear-mixed effect model.
|
Day -1 and Day 1 and Day 17
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Electrocardiographic parameters Delta PR
Time Frame: Day -1 and Day 1 and Day 17
|
A change from time-matched baseline measurements in PR interval will be determined on Day -1, Day 1 and Day 17.
|
Day -1 and Day 1 and Day 17
|
Electrocardiographic parameters Delta RR
Time Frame: Day -1 and Day 1 and Day 17
|
A change from time-matched baseline measurements in RR interval will be determined on Day -1, Day 1 and Day 17.
|
Day -1 and Day 1 and Day 17
|
Electrocardiographic parameters Delta QRS
Time Frame: Day -1 and Day 1 and Day 17
|
A change from time-matched baseline measurements in QRS interval will be determined on Day -1, Day 1 and Day 17.
|
Day -1 and Day 1 and Day 17
|
Electrocardiographic parameters Delta QTc Bazett (QTcB)
Time Frame: Day -1 and Day 1 and Day 17
|
Mean change from baseline in QTcB as measured based on triplicate electrocardiograms extracted from continuous 12-lead Holter monitor recordings after study drug intake.
|
Day -1 and Day 1 and Day 17
|
Electrocardiographic parameters T-wave morphology
Time Frame: Day -1 and Day 1 and Day 17
|
Number and percentage of participants with changes from baseline
|
Day -1 and Day 1 and Day 17
|
Electrocardiographic parameters U-wave morphology
Time Frame: Day -1 and Day 1 and Day 17
|
Number and percentage of participants with changes from baseline
|
Day -1 and Day 1 and Day 17
|
Incidence and severity of AE/SAE/AESI (rated based on CTCAE v5.0)
Time Frame: Day-1, Day 1 to Day 18
|
Participants will be monitored for safety during the Screening and Treatment Phases, and up to 30 days after the last dose of study drug.
From the end of treatment phase onward collection of AE will be limited to Grade 3 or higher, all SAE and AESI from the remainder of the study.
|
Day-1, Day 1 to Day 18
|
Pharmacokinetic parameter area under the plasma drug concentration-time curve (AUC) from time 0 to 24 hours
Time Frame: Day 1-2 and Day 17-18
|
Day 1-2 and Day 17-18
|
|
Pharmacokinetic parameter maximum concentration observed (Cmax)
Time Frame: Day 1-2 and Day 17-18
|
Day 1-2 and Day 17-18
|
|
Pharmacokinetic parameter time to reach Cmax (tmax)
Time Frame: Day 1-2 and Day 17-18
|
Day 1-2 and Day 17-18
|
|
Pharmacokinetic parameter minimum observed plasma concentration at steady-state (Cmin,ss)
Time Frame: Cmin,ss will only be collected on Day 17
|
Cmin,ss will only be collected on Day 17
|
|
Pharmacokinetic parameter accumulation ratio(Rac)
Time Frame: Day 1-2 and Day 17-18
|
Day 1-2 and Day 17-18
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 26, 2023
Primary Completion (Anticipated)
November 5, 2024
Study Completion (Anticipated)
November 5, 2024
Study Registration Dates
First Submitted
October 12, 2022
First Submitted That Met QC Criteria
November 1, 2022
First Posted (Actual)
November 7, 2022
Study Record Updates
Last Update Posted (Actual)
May 15, 2023
Last Update Submitted That Met QC Criteria
May 12, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR3680-I-QTc
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Castration-Resistant Prostate Cancer
-
Nuvation Bio Inc.WithdrawnProstate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic NeoplasmsUnited States
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Astellas Pharma IncPfizerCompletedCastration-resistant Prostate CancerJapan
-
Massachusetts General HospitalBayerCompletedProstate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to BoneUnited States
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Clarus TherapeuticsRecruitingProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
BAMF HealthRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Translational Research Center for Medical Innovation...CompletedCastration Resistant Prostate Cancer (CRPC)
Clinical Trials on SHR3680 tablets
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHormone Refractory Prostate Cancer | Metastatic Prostate CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.TerminatedProstate Cancer | Castration-resistant Prostate CancerChina
-
Atridia Pty Ltd.CompletedProstate Cancer | NeoplasmAustralia
-
Jiangsu HengRui Medicine Co., Ltd.UnknownProstate Cancer | Castration-resistant Prostate CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingHepatic Impairment | Healthy ParticipantsChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownProstate Cancer MetastaticChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingPatients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyChina
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam
-
Cara Therapeutics, Inc.RecruitingPruritus | Notalgia ParestheticaUnited States, Poland, Spain, Canada, Germany